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Objective
Sting challenge is the gold standard method to evaluate
the therapeutic efficiency of allergen specific immunother-
apy (ASIT) in hymenoptera venom allergic patients.
Unfortunately, this method is risky, expensive and time
consuming. Therefore, the development of an in vitro
method is desirable. Recently the basophil activation test
(BAT) performed with natural venom has been shown to
be a promising method. We aimed to improve the benefit
of BAT technology by applying the panel of recombinant
allergens Ves v 1, Ves v 2, Ves v 3 and Ves v 5.
Methods
BAT was performed in 83 patients with hymenoptera
venom allergy. Patients were evaluated before and one
year after starting SIT before the sting challenge.
Results
Natural venom and Ves v 5 recognise the majority of
wasp venom allergic patients. The BAT reactivity towards
natural venom and recombinant Ves v 5 is diminished
during ASIT. While the majority of patients without
allergic systemic reaction after the sting challenge did not
induce basophil activation towards natural venom,
patients with an allergic reaction after the sting challenge
were positive to BAT towards natural venom and Ves v
5. BAT performed with natural venom and recombinant
allergens is a promising in vitro method to predict suc-
cessful immunotherapy and new allergen sensitization of
patients upon allergen immuntherapy.
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